Driving reinvestment in R&D for antibiotics and advocating their responsible use


First 180 Days Draft Report on the US National Action Plan for Combating Antibiotic-Resistant Bacteria

In consultation with the Secretaries of Defense and Agriculture, the U.S. Department of Health and Human Services (HHS) Secretary’s establishment of the President’s Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) is one of several recent U.S. Government (USG) actions to respond to the threat. As stipulated in Executive Order 13676 and their Charter, the PACCARB advises the HHS Secretary on the programs and policies intended to support the implementation and evaluation of the National Action Plan (NAP) for Combating Antibiotic-Resistant Bacteria (CARB); all written reports created by the PACCARB will then be provided to the President by the HHS Secretary. DRIVE-AB Read more

R&D for Antibiotic Resistance & Infectious Diseases in China Supported by GSK

GlaxoSmithKline (GSK) will put up $29 million for a Beijing-based R&D institute to tackle antibiotic resistance and infectious disease health threats in China by working in tandem with academics and regulators. The Institute for Infectious Diseases and Public Health will draw on 20 in-house GSK researchers to start and will look to existing drugs in the U.K. drugmaker's portfolio as well as clinical trial stage work on HIV and multidrug-resistant bacterial infections, China Daily reported.   Click here to read the full story.    ...
Read more

Review on Antimicrobial Resistance report: Infection prevention, control and surveillance

The Review on Antimicrobial Resistance, chaired by economist Jim O’Neill and commissioned by UK Prime Minister David Cameron, has released its latest report on 22 March, titled, “Infection prevention, control and surveillance: Limiting the development and spread of drug resistance”. The report examines the central role that infection prevention, control and surveillance need to play in combating the rise of drug-resistant infections, based on the recognition that fundamental improvements in these areas are the key to sustainable gains in health outcomes. The paper looks first at the role of infection prevention in the community through...
Read more

DRIVE-AB Symposium at 17th International Congress on Infectious Diseases

The 17th International Congress on Infectious Diseases (ICID) is taking place in Hyderabad, India, from March 2-5, 2016. This year DRIVE-AB will be collaborating on a symposium titled, "New and recently approved antibiotics: Challenges and opportunities". The symposium will take place on Saturday, March 5 in Hall 2 from 10:15 - 12:15hrs and will be co-chaired by R. Rangarajan (India) and DRIVE-AB participant U. Theuretzbacher (Austria). Another DRIVE-AB participant, C. Årdal (Norway), will be giving a presentation during the symposium  on "Incentivising antibiotic innovation". New and Recently Approved Antibiotics: Challenges and Opportunities (in collaboration with DRIVE-AB- a project of the Innovative Medicines Initiative) Saturday,...
Read more

UK Review on Antimicrobial Resistance calls for wider use of vaccines & alternative approaches to drug-resistant infections

The UK Review on Antimicrobial Resistance, chaired by Jim O’Neill, released its latest report on February 11 2016, titled “Vaccines and alternative approaches: reducing our dependence on antimicrobials“. This latest in a series of reports by the Review on Antimicrobial Resistance sets out that there are too few vaccines and alternative approaches to antibiotics available for doctors to use to tackle many of our most urgent drug resistance threats, and that there is a need for further investment in the development of these products. The report provides an overview of the markets and the pipelines for...
Read more